Novel Multiplexed Plasma Biomarker Panel Has Diagnostic and Prognostic Potential in Children With Hypertrophic Cardiomyopathy.
Gabriella CapturIvan DoykovSheng-Chia ChungElla FieldAnnabelle BarnesEnpei ZhangImogen HeenanGabrielle NorrishJames C MoonPerry Mark ElliottWendy E HeywoodKevin A MillsJuan Pablo Pablo KaskiPublished in: Circulation. Genomic and precision medicine (2024)
In children, a 7-biomarker proteomics panel can distinguish HCM from controls with high sensitivity and specificity, and a second 4-biomarker panel identifies those at high risk of adverse arrhythmic outcomes, including sudden cardiac death.